278 related articles for article (PubMed ID: 24401154)
21. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
22. An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins.
Subramaniam A; Loo SY; Rajendran P; Manu KA; Perumal E; Li F; Shanmugam MK; Siveen KS; Park JI; Ahn KS; Hui KM; Kumar AP; Sethi G
Apoptosis; 2013 Oct; 18(10):1175-87. PubMed ID: 23700228
[TBL] [Abstract][Full Text] [Related]
23. Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance.
Bauer JA; Lupica JA; Didonato JA; Lindner DJ
Anticancer Res; 2020 Dec; 40(12):6751-6763. PubMed ID: 33288568
[TBL] [Abstract][Full Text] [Related]
24. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
25. Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines.
Matsuda T; Almasan A; Tomita M; Uchihara JN; Masuda M; Ohshiro K; Takasu N; Yagita H; Ohta T; Mori N
J Virol; 2005 Feb; 79(3):1367-78. PubMed ID: 15650163
[TBL] [Abstract][Full Text] [Related]
26. Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals.
Abou El Naga RN; Azab SS; El-Demerdash E; Shaarawy S; El-Merzabani M; Ammar el-SM
Life Sci; 2013 Mar; 92(10):555-61. PubMed ID: 23352978
[TBL] [Abstract][Full Text] [Related]
27. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.
Carlisi D; Lauricella M; D'Anneo A; Emanuele S; Angileri L; Di Fazio P; Santulli A; Vento R; Tesoriere G
Eur J Cancer; 2009 Sep; 45(13):2425-38. PubMed ID: 19643600
[TBL] [Abstract][Full Text] [Related]
29. ShDcR3 sensitizes TRAIL-resistant HCC cells by inducing caspase-dependent apoptosis while suppressing NF-κB dependent cFLIPL expression.
Liang DY; Huang W; Chang Q; Hou YQ
PLoS One; 2018; 13(2):e0191545. PubMed ID: 29444104
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
[TBL] [Abstract][Full Text] [Related]
31. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB.
Ou D; Wang X; Metzger DL; Robbins M; Huang J; Jobin C; Chantler JK; James RF; Pozzilli P; Tingle AJ
Hum Immunol; 2005 Jul; 66(7):799-809. PubMed ID: 16112027
[TBL] [Abstract][Full Text] [Related]
32. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
33. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
Szliszka E; Helewski KJ; Mizgala E; Krol W
Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
[TBL] [Abstract][Full Text] [Related]
34. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
Iacomino G; Medici MC; Russo GL
Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
[TBL] [Abstract][Full Text] [Related]
35. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
Chen JJ; Chou CW; Chang YF; Chen CC
J Immunol; 2008 Jun; 180(12):8030-9. PubMed ID: 18523266
[TBL] [Abstract][Full Text] [Related]
37. Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas.
Cavin LG; Wang F; Factor VM; Kaur S; Venkatraman M; Thorgeirsson SS; Arsura M
Mol Cancer Res; 2005 Jul; 3(7):403-12. PubMed ID: 16046551
[TBL] [Abstract][Full Text] [Related]
38. NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2.
Diessenbacher P; Hupe M; Sprick MR; Kerstan A; Geserick P; Haas TL; Wachter T; Neumann M; Walczak H; Silke J; Leverkus M
J Invest Dermatol; 2008 May; 128(5):1134-47. PubMed ID: 17989734
[TBL] [Abstract][Full Text] [Related]
39. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
40. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
Ma Y; Wang J; Liu L; Zhu H; Chen X; Pan S; Sun X; Jiang H
Cancer Lett; 2011 Feb; 301(1):75-84. PubMed ID: 21078540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
